{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:51:20Z","timestamp":1789829480314,"version":"4.0.1"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Peripheral T-cell lymphomas (PTCLs) are highly heterogeneous and present significant treatment challenges. Immune checkpoint therapies, such as PD-1 and CTLA-4 inhibitors, have significantly changed the clinical management paradigm of tumors. The roles of immune checkpoints in PTCL and related agents have been actively explored over recent years. PD-1 and PD-L1 expression is detectable in both PTCL and immune cells within the tumor microenvironment and forms the basis for the exploration of antibodies targeting these proteins. Such antibodies are currently being investigated in clinical trials to guide individualized therapy. PD-1\/PD-L1 inhibitors alone and in combination with chemotherapy, radiotherapy, or targeted therapy have shown broad clinical efficacy and improved the survival of cancer patients. Studies of other immune checkpoint proteins, such as CTLA-4, TIM-3, LAG-3, and TIGIT, are likely to provide potential novel targets for immunotherapy. Here, we review the role of and recent advances in immune checkpoint blockade in common subtypes of PTCL, focusing on the anti-tumor immune responses to PD-1\/PD-L1 blockers.<\/jats:p>","DOI":"10.3389\/fphar.2022.869488","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:00:27Z","timestamp":1650952827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Xi","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-Cell Lymphomas in a Large US Multicenter Cohort: Prognostication in the Modern Era Including Impact of Frontline Therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00428-014-1615-5","article-title":"Expression of PD-1 (CD279) and FoxP3 in Diffuse Large B-Cell Lymphoma","volume":"465","author":"Ahearne","year":"2014","journal-title":"Virchows Arch."},{"key":"B3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of Mutational Processes in Human Cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3892\/mco.2019.1805","article-title":"Pembrolizumab in Newly Diagnosed EBV-Negative Extranodal Natural killer\/T-Cell Lymphoma: A Case Report","volume":"10","author":"Asif","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-Cell Lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood-2019-126194","article-title":"A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","article-title":"PD-L1 Is Upregulated by EBV-Driven LMP1 through NF-\u03baB Pathway and Correlates with Poor Prognosis in Natural killer\/T-Cell Lymphoma","volume":"9","author":"Bi","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-small-cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular Mechanisms of T Cell Co-stimulation and Co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-020-00940-z","article-title":"SBRT Combined with PD-1\/PD-L1 Inhibitors in NSCLC Treatment: a Focus on the Mechanisms, Advances, and Future Challenges","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41586-018-0206-z","article-title":"Induction and Transcriptional Regulation of the Co-inhibitory Gene Module in T Cells","volume":"558","author":"Chihara","year":"2018","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41379-019-0392-8","article-title":"Immune Subtyping of Extranodal NK\/T-cell Lymphoma: a New Biomarker and an Immune Shift during Disease Progression","volume":"33","author":"Cho","year":"2020","journal-title":"Mod. Pathol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma after Prior Systemic Therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biocel.2018.03.004","article-title":"HDAC Inhibitors as Epigenetic Regulators for Cancer Immunotherapy","volume":"98","author":"Conte","year":"2018","journal-title":"Int. J. Biochem. Cel Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4049\/immunohorizons.1800083","article-title":"IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors","volume":"3","author":"DeLong","year":"2019","journal-title":"Immunohorizons"},{"key":"B18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40364-017-0093-8","article-title":"Utility of PD-L1 Immunohistochemistry Assays for Predicting PD-1\/PD-L1 Inhibitor Response","volume":"5","author":"Diggs","year":"2017","journal-title":"Biomark. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, A Third Member of the B7 Family, Co-stimulates T-Cell Proliferation and Interleukin-10 Secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7189","DOI":"10.2147\/OTT.S262039","article-title":"Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed\/Refractory Natural Killer\/T-Cell Lymphoma: A Report of Three Cases","volume":"13","author":"Du","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world Data on Prognostic Factors and Treatment in Peripheral T-Cell Lymphomas: a Study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.14670\/HH-11-931","article-title":"Expression of TIM-3 and LAG-3 in Extranodal NK\/T Cell Lymphoma, Nasal Type","volume":"33","author":"Feng","year":"2018","journal-title":"Histol. Histopathol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1084\/jem.20081811","article-title":"CD4+ Regulatory T Cells Require CTLA-4 for the Maintenance of Systemic Tolerance","volume":"206","author":"Friedline","year":"2009","journal-title":"J. Exp. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1111\/ajt.12834","article-title":"Understanding the CD28\/CTLA-4 (CD152) Pathway and its Implications for Costimulatory Blockade","volume":"14","author":"Gardner","year":"2014","journal-title":"Am. J. Transpl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1593\/neo.05733","article-title":"The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors","volume":"8","author":"Ghebeh","year":"2006","journal-title":"Neoplasia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood-2012-10-385591","article-title":"The Role of B7 Family Molecules in Hematologic Malignancy","volume":"121","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.3892\/ol.2014.2356","article-title":"Role of Programmed Death Ligands in Effective T-Cell Interactions in Extranodal Natural killer\/T-Cell Lymphoma","volume":"8","author":"Han","year":"2014","journal-title":"Oncol. Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic Drivers of Oncogenic Pathways in Molecular Subgroups of Peripheral T-Cell Lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective Responses in Relapsed T-Cell Lymphomas with Single-Agent Brentuximab Vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year Results of a Randomized, Phase III Study of Brentuximab Vedotin with Chemotherapy for CD30-Positive Peripheral T-Cell Lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2019-121865","article-title":"Preliminary Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (Pts) with Relapsed or Refractory Extranodal Natural Killer\/T Cell Lymphoma (Rr-ENKTL)","volume":"134","author":"Huang","year":"2019","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the Major Histocompatibility Complex Class II Binding Site on LAG-3 Protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B35","doi-asserted-by":"publisher","first-page":"100326","DOI":"10.18632\/oncotarget.22222","article-title":"Co-targeting aurora Kinase with PD-L1 and PI3K Abrogates Immune Checkpoint Mediated Proliferation in Peripheral T-Cell Lymphoma: a Novel Therapeutic Strategy","volume":"8","author":"Islam","year":"2017","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood-2019-132278","article-title":"A Phase I\/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3w) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)","volume":"134","author":"Iyer","year":"2019","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2020-143252","article-title":"A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1073\/pnas.0910341107","article-title":"Dual Function of CTLA-4 in Regulatory T Cells and Conventional T Cells to Prevent Multiorgan Autoimmunity","volume":"107","author":"Jain","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00277-016-2818-4","article-title":"Expression of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 in Extranodal NK\/T-cell Lymphoma, Nasal Type","volume":"96","author":"Jo","year":"2017","journal-title":"Ann. Hematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its Ligands in Tolerance and Immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00428-016-2011-0","article-title":"Expression of Programmed Cell Death Ligand 1 (PD-L1) in Advanced Stage EBV-Associated Extranodal NK\/T Cell Lymphoma Is Associated with Better Prognosis","volume":"469","author":"Kim","year":"2016","journal-title":"Virchows Arch."},{"key":"B42","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/jdv.14165","article-title":"Expression of Programmed Death-1 in Cutaneous Extranodal Natural killer\/T-Cell Lymphoma and its Effect on Clinical Findings and Biological Behaviour","volume":"31","author":"Kim","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13045-018-0687-0","article-title":"Treatment of Localized Extranodal NK\/T Cell Lymphoma, Nasal Type: a Systematic Review","volume":"11","author":"Kim","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4143\/crt.2018.191","article-title":"Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus\u2012Positive and \u2012Negative Relapsed or Refractory Non-hodgkin Lymphomas","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"B45","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/hon.2924","article-title":"Comparison of First-Line Treatments of Peripheral T-Cell Lymphoma According to Regimen: A Systematic Review and Meta-Analysis","volume":"39","author":"Kim","year":"2021","journal-title":"Hematol. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00428-020-02790-z","article-title":"Clinicopathological Features of Programmed Cell Death-1 and Programmed Cell Death-Ligand-1 Expression in the Tumor Cells and Tumor Microenvironment of Angioimmunoblastic T Cell Lymphoma and Peripheral T Cell Lymphoma Not Otherwise Specified","volume":"477","author":"Kim","year":"2020","journal-title":"Virchows Arch."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the Treatment of Relapsed or Refractory Extranodal NK\/T-cell Lymphoma: an Open-Label Phase 2 Study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/ddg.14142","article-title":"Sustained Complete Remission of Extranodal NK\/T-cell Lymphoma, Nasal Type, Following Pembrolizumab and Radiation Therapy","volume":"18","author":"Klee","year":"2020","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor Mutational burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: a Review of Current Evidence","volume":"25","author":"Klempner","year":"2019","journal-title":"Oncologist"},{"key":"B50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/PAS.0b013e3181cc7e79","article-title":"PD-1 Expression in T-Cell Lymphomas and Reactive Lymphoid Entities: Potential Overlap in Staining Patterns between Lymphoma and Viral Lymphadenitis","volume":"34","author":"Krishnan","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/his.12882","article-title":"Clinicopathological Analysis of Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Expression in the Tumour Microenvironments of Diffuse Large B Cell Lymphomas","volume":"68","author":"Kwon","year":"2016","journal-title":"Histopathology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for Natural killer\/T-Cell Lymphoma: Analysis of Safety and Efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 Blockade with Pembrolizumab Is Highly Effective in Relapsed or Refractory NK\/T-cell Lymphoma Failing L-Asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and Saturation Analysis of Cancer Genes across 21 Tumour Types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in Patients with Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of Pembrolizumab in Relapsed\/refractory NK\/T-cell Lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.21203\/rs.3.rs-51226\/v1","article-title":"Clinical Significance of Circulating Exosomal PD-L1 and Soluble PD-L1 in Extranodal NK\/T-cell Lymphoma, Nasal-type","volume":"10","author":"Li","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1038\/s41375-020-1000-0","article-title":"Whole-genome Sequencing Identifies Responders to Pembrolizumab in Relapse\/refractory Natural-Killer\/T Cell Lymphoma","volume":"34","author":"Lim","year":"2020","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.21147\/j.issn.1000-960410.21147\/j.issn.1000-9604.2020.03.03","article-title":"Immune Checkpoint Inhibitors in Malignant Lymphoma: Advances and Perspectives","volume":"32","author":"Lin","year":"2020","journal-title":"Chin. J. Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-017-0479-y","article-title":"Clinical Applications of PD-L1 Bioassays for Cancer Immunotherapy","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00280-018-3744-z","article-title":"A Retrospective Study of the CHOP, CHOPE, and CHOPE\/G Regimens as the First-Line Treatment of Peripheral T-Cell Lymphomas","volume":"83","author":"Liu","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1002\/cam4.3037","article-title":"Improving Survival of 3760 Patients with Lymphoma: Experience of an Academic center over Two Decades","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1005642","DOI":"10.1371\/journal.ppat.1005642","article-title":"PD-1\/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model","volume":"12","author":"Ma","year":"2016","journal-title":"Plos Pathog."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of Patients with Peripheral T-Cell Lymphoma after First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.critrevonc.2017.06.001","article-title":"Biomarkers of Response to PD-1\/PD-L1 Inhibition","volume":"116","author":"Maleki Vareki","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a Key Inhibitor of the Cancer Immunity Cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1080\/10428194.2021.1881511","article-title":"PD-L1 Expression in Peripheral T-Cell Lymphomas Is Not Related to Either PD-L1 Gene Amplification or Rearrangements","volume":"62","author":"Manso","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"B68","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13148-017-0358-y","article-title":"Epi-drugs in Combination with Immunotherapy: a New Avenue to Improve Anticancer Efficacy","volume":"9","author":"Mazzone","year":"2017","journal-title":"Clin. Epigenetics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1182\/blood-2020-138542","article-title":"Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: the Largest Multicenter Retrospective Analysis","volume":"136","author":"Mehta-Shah","year":"2020","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1016\/j.humpath.2009.03.025","article-title":"Increased Programmed Death-1+ Tumor-Infiltrating Lymphocytes in Classical Hodgkin Lymphoma Substantiate Reduced Overall Survival","volume":"40","author":"Muenst","year":"2009","journal-title":"Hum. Pathol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000500974","article-title":"Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer\/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance","volume":"143","author":"Muhamad","year":"2020","journal-title":"Acta Haematol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1136\/jclinpath-2019-206117","article-title":"Expression of the Checkpoint Receptors LAG-3, TIM-3 and VISTA in Peripheral T Cell Lymphomas","volume":"73","author":"Murga-Zamalloa","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00262-017-1987-x","article-title":"Programmed Death-Ligand 1 and its Soluble Form Are Highly Expressed in Nasal Natural killer\/T-Cell Lymphoma: a Potential Rationale for Immunotherapy","volume":"66","author":"Nagato","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1158\/0008-5472.CAN-11-0096","article-title":"Anti-TIM3 Antibody Promotes T Cell IFN-\u03b3-Mediated Antitumor Immunity and Suppresses Established Tumors","volume":"71","author":"Ngiow","year":"2011","journal-title":"Cancer Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the Pivotal PROPEL Study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.humpath.2017.10.029","article-title":"Programmed Death-1 Ligands PD-L1 and PD-L2 Show Distinctive and Restricted Patterns of Expression in Lymphoma Subtypes","volume":"71","author":"Panjwani","year":"2018","journal-title":"Hum. Pathol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T Cell Exhaustion in Infection and Cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year Results of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7150\/jca.37033","article-title":"High Expression Levels of TLR9 and PD-L1 Indicates a Poor Prognosis in Patients with Angioimmunoblastic T-Cell Lymphoma: a Retrospective Study of 88 Cases in a Single center","volume":"11","author":"Qian","year":"2020","journal-title":"J. Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a Molecular Basis for the Cell-Extrinsic Function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood.201900203810.1056\/NEJMc1803181","article-title":"Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","article-title":"Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo","volume":"177","author":"Read","year":"2006","journal-title":"J. Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 Pathways to Reverse T Cell Exhaustion and Restore Anti-tumor Immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/cts.12455","article-title":"Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch","volume":"10","author":"Scheerens","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: An Analysis of Patients with T-Cell Lymphoma Treated in Studies of the German High-Grade Non-hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/16078454.2019.1590965","article-title":"Soluble Programmed Death-Ligand 1 are Highly Expressed in Peripheral T-Cell Lymphoma: a Biomarker for Prognosis","volume":"24","author":"Shen","year":"2019","journal-title":"Hematology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and Safety of Geptanolimab (GB226) for Relapsed or Refractory Peripheral T Cell Lymphoma: an Open-Label Phase 2 Study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1002\/ijc.23042","article-title":"Augmented Expression of Programmed Death-1 in Both Neoplastic and Non-neoplastic CD4+ T-Cells in Adult T-Cell Leukemia\/lymphoma","volume":"121","author":"Shimauchi","year":"2007","journal-title":"Int. J. Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B94","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41379-021-00884-w","article-title":"Quantitative Comparison of PD-L1 IHC Assays against NIST Standard Reference Material 1934","volume":"35","author":"Sompuram","year":"2022","journal-title":"Mod. Pathol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1182\/blood-2018-01-829424","article-title":"Oncogenic Activation of the STAT3 Pathway Drives PD-L1 Expression in Natural killer\/T-Cell Lymphoma","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of Lymphoid Neoplasms in China: Analysis of 4,638 Cases According to the World Health Organization Classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1080\/10428194.2019.1602266","article-title":"The Prognostic Value of Toll-like Receptor5 and Programmed Cell Death-Ligand1 in Patients with Peripheral T-Cell Non-hodgkin Lymphoma","volume":"60","author":"Sun","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B98","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B99","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for Relapsed\/refractory Extranodal NK\/T Cell Lymphoma: A Multicenter, Single-Arm, Phase 2 Trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal. Transduct. Target. Ther."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","article-title":"Treg-expressed CTLA-4 Depletes CD80\/CD86 by Trogocytosis, Releasing Free PD-L1 on Antigen-Presenting Cells","volume":"118","author":"Tekguc","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-Term Follow-Up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res."},{"key":"B102","doi-asserted-by":"publisher","first-page":"709s","DOI":"10.1158\/1078-0432.CCR-06-1868","article-title":"Implications of B7-H1 Expression in clear Cell Carcinoma of the Kidney for Prognostication and Therapy","volume":"13","author":"Thompson","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.4161\/21645515.2014.983409","article-title":"PD-1 and PD-L1 Antibodies for Melanoma","volume":"10","author":"Tsai","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"B104","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International Peripheral T-Cell and Natural killer\/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"33035","DOI":"10.18632\/oncotarget.8847","article-title":"High post-treatment Serum Levels of Soluble Programmed Cell Death Ligand 1 Predict Early Relapse and Poor Prognosis in Extranodal NK\/T Cell Lymphoma Patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B106","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00277-017-3176-6","article-title":"PD-1-PD-L1 Immune-Checkpoint Blockade in Malignant Lymphomas","volume":"97","author":"Wang","year":"2018","journal-title":"Ann. Hematol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a Haploinsufficient Suppressor of T Cell Lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and Cellular Insights into T Cell Exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric junction Cancer: An Open-Label, Dose Escalation and Expansion Study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"608304","DOI":"10.3389\/fonc.2020.608304","article-title":"Durable Response to Sintilimab and Chidamide in a Patient with Pegaspargase- and Immunotherapy-Resistant NK\/T-Cell Lymphoma: Case Report and Literature Review","volume":"10","author":"Yan","year":"2020","journal-title":"Front. Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e271","DOI":"10.3324\/haematol.2016.148015","article-title":"Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al","volume":"101","author":"Yoo","year":"2016","journal-title":"Haematologica"},{"key":"B112","doi-asserted-by":"publisher","first-page":"100126","DOI":"10.1016\/j.lanwpc.2021.100126","article-title":"Comprehensive Analysis of Peripheral T-Cell and Natural killer\/T-Cell Lymphoma in Asian Patients: A Multinational, Multicenter, Prospective Registry Study in Asia","volume":"10","author":"Yoon","year":"2021","journal-title":"Lancet Reg. Health West. Pac."},{"key":"B113","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00277-019-03643-9","article-title":"The Correlation of Clinicopathological Features and Prognosis in Extranodal Natural Killer\/T Cell Lymphoma: a Report of 42 Cases in the Early Stage","volume":"98","author":"Zeng","year":"2019","journal-title":"Ann. Hematol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/cam4.2097","article-title":"Circulating PD-1 (+) Cells May Participate in Immune Evasion in Peripheral T-Cell Lymphoma and Chidamide Enhance Antitumor Activity of PD-1 (+) Cells","volume":"8","author":"Zhang W","year":"2019","journal-title":"Cancer Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/hon.2636","article-title":"Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas","volume":"37","author":"Zhang","year":"2019","journal-title":"Hematol. Oncol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.2174\/0929867324666170801102124","article-title":"Histone Deacetylase Inhibitors in Tumor Immunotherapy","volume":"26","author":"Zhao","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"B119","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice with Disseminated Acute Myelogenous Leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"97671","DOI":"10.18632\/oncotarget.18311","article-title":"Soluble PD-1 and PD-L1: Predictive and Prognostic Significance in Cancer","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.869488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:00:31Z","timestamp":1650952831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.869488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":120,"alternative-id":["10.3389\/fphar.2022.869488"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.869488","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"article-number":"869488"}}